Valentis Pockets $14M in Public Offering

Dec 27, 2001

NEW YORK, Dec. 27 - Valentis has pocketed $13.8 million in an underwritten public offering of its common stock, the company said on Thursday.

Valentis offered the 6,130,007 shares, and Wells Fargo Van Kasper acted as underwriter.

In October, Burlingame, Calif.-based Valentis gave Pfizer a non-exclusive, research-only license to its GeneSwitch gene-regulation technology.

The GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures.

Breaking News

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.